Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

Phase: N/A Priority: Normal
NCT ID: NCT02059642 Org: User:
Start: 03/31/14 End: 09/30/14 Due: 09/30/15

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

Phase: N/A Priority: Normal
NCT ID: NCT01685281 Org: User:
Start: 08/31/13 End: 12/31/13 Due: 12/31/14

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02189772 Org: User:
Start: 08/31/14 End: 01/31/15 Due: 01/31/16

Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)

Phase: N/A Priority: Normal
NCT ID: NCT01243242 Org: User:
Start: 02/28/11 End: 09/30/11 Due: 09/30/12

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00995085 Org: User:
Start: 10/31/09 End: 10/31/10 Due: 10/31/11

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02126995 Org: User:
Start: 06/30/14 End: 06/30/15 Due: 06/30/16

The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD

Phase: N/A Priority: Normal
NCT ID: NCT02477748 Org: User:
Start: 06/30/15 End: 01/31/17 Due: 01/31/18

A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01933997 Org: User:
Start: 08/31/13 End: 10/31/13 Due: 10/31/14